AbbVie Stock News

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued.

Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.

AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.

AbbVie is a Dividend King that's proven it can successfully navigate patent cliffs. Brookfield Infrastructure offers attractive distributions and has a solid long-term growth strategy.

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versus 20x for ABBV, and we think this gap in valuation will narrow in favor of Pfizer in the coming years.

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection.

BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety profile and robust clinical trials demonstrating BOTOX® Cosmetic is effective in reducing the prominence of the masseter muscle.

UnitedHealth Group said on Tuesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.